By engaging in value-based programmes and collaborations that support proactive and preventive care, Amgen is working to improve sustainability and efficiencies in healthcare systems, while advancing patient and population outcomes.
Amgen’s value-based partnerships identify mutually beneficial opportunities to unlock value for the healthcare system and society worldwide. We believe that value-based partnerships are the key to unlocking real possibilities to improve healthcare provision and outcomes.
Creating a more sustainable high-quality healthcare system will require transformative change to a value-based healthcare model where the focus shifts from short-term budgeting and spending on inputs to one that’s concentrated on quality, efficiency and improving patient outcomes.
Key to success with a value-based healthcare model that reduces costs, improves care and enhances patient experiences is collaboration between organizations who recognize each other’s complementary expertise, experience and capabilities.
These collaborative working relationships are known by Amgen as value-based partnerships: two or more organizations sharing a mutually beneficial endeavor to deliver the highest value to the healthcare system and patients by focusing on improving patient outcomes while lowering system and societal total costs.
Amgen has already made a conscious shift from the traditional industry position of being a transactional supplier of medicines and is prioritizing funding for activities that make us a collaborative partner within the healthcare ecosystem.
Opportunities for value-based partnerships can be found across the healthcare system. Examples are:
Applying molecular testing to enable precision medicine and RAS gene testing and minimal residual disease (MRD) testing
Overview: Key oncology centers and hospitals in the UK, Germany, France and Spain conducting in-center testing for the RAS gene mutation found in cancers such as metastatic colorectal cancer (mCRC) and non-small cell lung cancer (NSCLC).
Key Takeaway: Dramatic decrease in turn-around time in the UK for RAS mutation status analysis in mCRC, from an average of 27 days to 2-3 days, surpassing the original target of a 30 per cent reduction, with this testing model now recognized as best practice. Implementing this technology delivered shortened timelines including faster tissue analyses with faster turn-around time, speedier diagnosis and decisions about appropriate therapy initiation.
We are also driving standardization of testing for MRD, a new surrogate endpoint for Progression Free Survival (PFS) in acute lymphoblastic leukemia (ALL), and newly diagnosed multiple myeloma (NDMM) patients via a centralized network of laboratories in Italy and Spain. Establishing rapid MRD assessment in participating hospitals has resulted in optimized and risk-driven therapeutic decision-making and improved quality of care for patients.
Insights from these programmes led to further innovative solutions to support cancer patients beyond their therapy including:
MiMomento partnership with academic hospitals, psycho-oncologists and patients in Spain leveraging a newly co-developed mindfulness app to address the high prevalence of anxiety and depression in patients with multiple myeloma.
Home infusion programs in Sweden, Italy and France providing installation of an easy-to-use pump system to allow patients to perform one of their twice-weekly infusions from home, reducing patient stress and travel time while reducing the administrative burden on hospital staff.
Using AI to improve patient risk stratification and prediction - CV AI
Overview: Harnessing the power of data, Amgen uses AI and machine learning to improve patient identification, optimize clinical development to improve risk stratification in Myocardial infarction (MI) patients and identify what drives individual risk and how treatment can be optimized. We plan to scale the approach by testing an algorithm in Real World Data (RWD).
Key Takeaway: Ambition to use cross-validated outcomes from clinical trials and RWD insights to better predict
post-MI patients with most urgent need to treat. Plan to scale approach to other areas of unmet need including bone metastasis, multiple myeloma and NSCLC.
Insights from our approach to Innovation have led to further innovative solutions to support post-MI patients beyond their therapy including:
Strengthening ecosystem for post fracture care - Capture the Fracture
Overview: Partnership with International Osteoporosis Foundation, University of Oxford and UCB to implement framework for fracture liaison services across 17 countries by the end of 2021. The Capture the Fracture® Partnership proactively implements post-fracture care coordination programs in hospitals and healthcare systems, to help prevent subsequent fractures due to osteoporosis, and improve patient care. With the aim of reducing the incidence of hip and vertebral fractures due to osteoporosis by 25% by 2025, the program provides virtual and in-person local mentorship and learning and driving policy change.
Key Takeaway: 500+ post-fracture care programs across 17 countries worldwide with 55% increased number of patients reached and 50% increase in post-fracture treatment rates by 2021. Fracture Liaison Service programs have already been initiated in nine countries across Europe.
Insights from these programs led to further innovative solutions to support osteoporosis patients beyond their therapy including: